Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail. H2 2021 and Full Year Results Grifols demonstrates resilient performance despite a challenging backdrop while recovery in plasma collection gains momentum Full year sales of EUR 4,933 million, adjusted EBITDA1 of EUR 1,014 million, with operating cash flow of EUR 597 million Barcelona, February 28, 2022.- Grifols (MCE: GRF, MCE: GRF .P, NASDAQ: GRFS) reported 2021 revenues of EUR 4,933.1 million, a 3.7% cc2 decline (-7.6% reported), in a year marked by the company’s resilience and unwavering efforts to offset extraordinary COVID-19 challenges resulting in reduced plasma volumes. 1 Excludes transaction, restructuring and divestment costs 2 Operating or constant currency (cc) excludes changes rate variations reported in the period • COVID-19 was the primary driver of reduced plasma volumes resulting in an extraordinary financial impact • Robust underlying demand across key proteins, coupled with mid-single-digit price increases, solid performance of key proteins and contribution from new products, partially offset plasma supply constraints • Bioscience revenues declined by 5.9% cc due to plasma supply restrictions, while other divisions increased: Diagnostic (3.5% cc), Hospital (20.3% cc) and Bio Supplies (4.8% cc) • Extensive measures taken to offset the impact of the pandemic were effective: COVID-19 tests sales, contribution from new products, price increases and operational savings plan • Margins impacted by lower plasma volumes and higher cost per liter, as well as costs derived from the integration of newly acquired companies and inflationary pressures, resulting in an adjusted EBITDA margin of 20.6% • Grifols’ fundamentals remain strong, reflected on an underlying EBITDA of EUR 1,570 million and 27.6% margin (28.1% in 2020) • Reported net profit totaled EUR 183 million, reflecting the impact of COVID-19 • Recovery in plasma collections under way - increasing 4% in the last three quarters, a positive trend we expect to see accelerate through 2022 • Enhancing plasma volumes through expansion of plasma capacity (+2 million liters) and capabilities. Measures in place to reinforce plasma supply as collections fully recover, as well as underpinning innovation, while streamlining the organization • Grifols is in a sound financial position, and is well invested to support sustainable growth • Grifols to acquire Biotest: a unique opportunity to strengthen its positioning by accelerating and broadening its pipeline and commercial footprint. The Public Tender Offer has achieved so far over 96% of voting rights and 70% of share capital

Page 2 of 4 Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail. Grifols reported EUR 2,396.5 million in revenues in the second half of 2021, a 9.8% cc decrease (-10.0%), with the fourth quarter significantly better than the third. Bioscience and Diagnostic divisions were affected by lower plasma collections in the first half of the year and lower year-on-year COVID-19 tests sales compared to the second half of 2020, respectively. Hospital and Bio Supplies divisions reported growth in the second half. Plasma collections increased by 4% in the last three quarters of the year (-4% in 2021 overall) mainly driven by acquired and new centers, which will collectively provide 2 million liters of additional capacity per year. This positive trend has continued and is expected to accelerate throughout 2022 as the industry recovery trend gains strength. This expected acceleration builds on measures in place to grow plasma supply, including: further contribution from new and acquired centers, a new donor compensation scheme, greater talent retention and digital improvements resulting in optimized headcount, software automation and flow- time reductions, as well as digital marketing enhancements. The Bioscience Division reported a 5.9% cc decline (-10.1%) in revenues to EUR 3,815.0 million at year-end, and a -12.0% cc decline (-12.2%) in the second half to EUR 1,829.0 million. Robust underlying demand across key proteins, coupled with mid-single-digit price increases, solid performance of Alpha-1, Albumin and specialty proteins, and contribution from new products, partially offset plasma supply constraints. These impacted immunoglobulins’ volume growth, specially in the second half of the year. Xembify® showed higher demand, while Vistaseal™ and Tavlesse® gained traction, and ALBUTEIN FlexBag™ was launched in November. Diagnostic Division revenues grew by 3.5% cc (0.4%) to EUR 779.1 million in 2021, despite the 11.7% cc decline (-12.0%) to EUR 383.6 million in the second half. The TMA (Transcription-Mediated Amplification) molecular test to detect the SARS-CoV-2 virus and Blood Typing Solutions were core growth drivers, offsetting the impact of the mandatory termination of Zika testing in blood and plasma donations. Hospital Division revenues grew by 20.3% cc (19.0%) to EUR 141.2 million in 2021. The Division reported robust growth in the second half, expanding by 21.2% cc (20.8%) to EUR 73.4 million. The Division’s positive performance was driven by all business lines as hospital investments return to normal levels. Bio Supplies Division revenues increased by 4.8% cc (0.7%) to EUR 225.8 million in 2021, reinforced by a 22.0% cc growth (21.7%) to EUR 118.5 million in the second half of the year, mainly fueled by higher third-party plasma sales, followed by NTU albumin and cell culture media. The gross margin in 2021 stood at 39.8% (42.2% in 2020) and 35.4% in the second half, impacted by lower plasma volumes and higher cost per liter as a result of lower absorption of fixed costs and higher donor compensation. Grifols expects cost per liter to gradually decrease as plasma collection volumes recover. Reported EBITDA reached EUR 961.5 million with a 19.5% margin in 2021 (EUR 327.0 million and 13.6% in the second half), compared to EUR 1,324.0 million and 24.8% in 2020. The adjusted EBITDA margin represented 20.6% of revenues. In addition to the aforementioned impacts, EBITDA was affected by higher operating expenses following the integration of newly acquired companies,

Page 3 of 4 Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail. including Alkahest and GigaGen to reinforce Grifols’ innovation assets, transaction and restructuring costs, and inflationary pressures. Grifols’ efforts to become a leaner organization are mirrored in its operating cost containment plan. In line with the company’s commitment, EUR 40 million in cost reductions were achieved in 2021, while additional EUR 60 million and EUR 40 million are expected to be realized in 2022 and 2023, respectively. Furthermore, savings of EUR 40 million related to R+D prioritization are also expected in 2022, while the company continues to divest in non-strategic assets. The estimated COVID-19 net impact on EBITDA totaled EUR 503 million in 2021, primarily stemming from lower plasma volumes of EUR 420 million: lower sales (EUR 238 million) and lower absorption of fixed costs (EUR 183 million). Additionally, a higher donor compensation had an estimated impact of EUR 150 million and COVID-19 test sales positively contributed to EBITDA in EUR 68 million. Excluding COVID-19 impacts, transaction and restructuring costs (EUR 52 million) and exchange rate variations (EUR 54 million), underlying EBITDA totaled EUR 1,570 million at 27.6% margin (EUR 1,544 million at 28.1% in 2020). Grifols anticipates a return to growth and improved profitability as plasma collections normalize. Revenues and margins are expected to progressively improve throughout 2022, backed by geographic and product mix, strong underlying demand, a favorable pricing environment and reduced cost per liter through realization of scale efficiencies further supported by ongoing efforts to streamline the organization. Grifols continues to reinforce its innovation strategy within plasma and non-plasma assets, developing a risk-value balanced portfolio. In this context, total net investment in R+D+i amounted to EUR 329.3 million (EUR 174.0 million in the second half), representing 6.7% of revenues. The integration of Alkahest and GigaGen platforms will notably bolster and diversify Grifols’ pipeline. In terms of CAPEX, the company allocated EUR 280.9 million in 2021 (EUR 163.6 million in the second half). The financial result stood at EUR 277.8 million in 2021 (EUR 158.4 million in the second half), an increase resulting from the issuance of senior unsecured bonds to finance the Biotest AG investment in the equivalent amount of EUR 2,000 million. Share of results of equity-accounted investees mainly included the write-up of the GigaGen investment (EUR 34.5 million), following the purchase agreement in the first quarter of 2021 to acquire the remaining capital. The reported net profit totaled EUR 182.8 million (EUR 618.5 million in 2020), reflecting COVID-19 impact. Excluding the impact of IFRS 163, net financial debt reached EUR 5,828.0 million and the leverage ratio stood at 5.4x. Excluding COVID-19 impacts the ratio was 3.7x. The ratio increased throughout the year as a result of strategic acquisitions totaling EUR 520 million to secure plasma supply and reinforce innovation projects. Decreasing leverage remains a priority, aiming to reduce its ratio to <4x in 2023 and <3.5x in 2024. 3 As of December 31, 2021, the impact of IFRS 16 on total debts stands at EUR 874 million

Page 4 of 4 Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail. As of December 31, 2021, Grifols’ liquidity position to EUR 1,277 million, including a cash position totaled EUR 655 million. Grifols remains committed to its long-term vision and delivering value to its stakeholders, with fundamentals unchanged. Moving forward, the company will leverage its efforts to increase its plasma supply, expand and diversify into new markets and foster innovation, while maintaining financial discipline and becoming a leaner organization. About Grifols Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services that are sold in more than 110 countries. Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 23,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. In 2021, Grifols’ economic impact in its core countries of operation was EUR 7.7 billion. The company also generated 141,500 jobs, including indirect and induced jobs. The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information about Grifols, please visit www.grifols.com

2021 Full Year Results February 28, 2022 Invested for the Future

- 2 - 2021 Full Year Results Important information This presentation does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Spanish Securities Market Law (Royal Legislative Decree 4/2015, of 23 October, as amended and restated from time to time), Royal Decree 1310/2005, of November 4, and its implementing regulations. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any other jurisdiction. Forward-looking Statements This presentation contains forward-looking information and statements about GRIFOLS based on current assumptions and forecast made by GRIFOLS management, including pro forma figures, estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expected”, “potential”, “estimates” and similar expressions. Although Grifols believes that the expectations reflected in such forward-looking statements are reasonable, various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the Company and the estimates given here. These factors include those discussed in our public reports filed with the Comisión Nacional del Mercado de Valores and the Securities and Exchange Commission, which are accessible to the public. The Company assumes no liability whatsoever to update these forward-looking statements or conform them to future events or developments. Forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of Grifols. Given the significant business disruption we are experiencing we believe that the company is not in a position to make forward looking statements. Any forward looking statements issued by the company and, in particular, those contained in the Biotest presentation of September 17, 2021 are no longer valid and should not be taken into account by our shareholders or investors. NON-GAAP Financial Measures This presentation refers to certain non-GAAP financial measures. The presentation of these financial measures is not intended to be considered in isolation, or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. In addition, these measures may be different from non- GAAP financial measures used by other companies, limiting their usefulness for comparative purposes. We compensate for these limitations by providing specific information regarding GAAP amounts excluded from these non-GAAP financial measures.A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in our Grifols Financial Statements. Legal Disclaimer

1. Introduction

- 4 - 2021 Full Year Results … through 4 divisions… Grifols Mission: Improving People’s Health and Well-being Bioscience Diagnostic Bio Supplies and our COMMITMENT to… Hospital Donors Society Environment Our People Patients Innovation Ethical Leadership

- 5 - 2021 Full Year Results Driven by Our Transformational Strategy … And Strong Underlying Fundamentals Plasma at the core Accelerating Innovation Industrial excellence Global expansion Leading player in the global plasma market with strong position in the U.S. Strengthening global presence in China through SRAAS strategic alliance, Europe, Middle East and Africa, and Canada Global 360+ plasma-centers Enough plasma centers and industrial capacity to support underlying demand Reinforced pipeline to deliver a risk-value balanced portfolio Switching gears to a more lean, flexible and dynamic organization … backed by 4 Pillars… Lean organization

2. Financial performance

- 7 - 2021 Full Year Results 2021 Highlights A reduction in plasma volumes resulting from COVID-19 was the leading factor that drove extraordinary financial impacts Support recovery in plasma collections, accelerate innovation while creating a leaner organization with strong operational execution Revenue Reduction in plasma volumes triggered the decrease in IG volume growth, which was partially offset by price increases and NAT COVID-19 tests Margins Impacted by lower plasma volumes and higher cost per liter, in addition to higher opex following the integration of newly acquired companies, transaction and restructuring costs, and inflationary pressures Deleveraging Leverage ratio at 5.4x and 3.7x excluding COVID-19 impacts Commitment to deleverage to <4x by 2023 and <3.5x by 2024 Accelerating Innovation New leadership to effectively foster and support breakthrough innovation Reinforcing innovation ecosystem integrating Alkahest and GigaGen Unique opportunity to strengthen Grifols’ leading position Biotest Note: all growths at constant currency (cc), which excludes exchange rate fluctuations period over period, and vs. PY

- 8 - 2021 Full Year Results 2021 Highlights Full Year Performance Marked by a Challenging Second Half H1’21 H2’21 2021 Revenue 2,536.6 2,396.5 4,933.1 % Growth +2.3% (9.8%) (3.7%) Gross Margin 1,114.1 848.5 1,962.6 % Margin 43.9% 35.4% 39.8% R&D 158.5 196.3 354.8 SG&A 507.0 554.5 1.061,5 EBITDA 634.5 327.0 961.5 % Margin 25.0% 13.6% 19.5% EBITDA Adjusted 637.0 377.0 1,014.0 % Margin 25.1% 15.8% 20.6% Group Profit 266.8 (84.0) 182.8 Lower plasma collections in H1 fully impacted revenues in H2. Q4 significantly better than Q3 Lower plasma volume and higher cost per liter (mainly due to the operational leverage) in 1H impacted margins in 2H. Partially offset by stronger COVID test sales and price increases R&D reported increased investments due to the integration of Alkahest and GigaGen Higher SG&A in 2H due to transaction and restructuring costs, higher freights and inflationary pressures. Impact of the integration of newly acquired companies Net Profit in H2 impacted by higher financial expenses (mainly new HYB) and higher effective tax rate Note: all growths at constant currency (cc), which excludes exchange rate fluctuations period over period, and vs. PY (EUR in millions)

- 9 - 2021 Full Year Results H1’21 H2’21 2021 Bioscience 1,986.0 1,829.0 3,815.0 % Growth (0.1%) (12.0%) (5.9%) Diagnostic 395.5 383.6 779.1 % Growth +22.9% (11.7%) +3.5% Hospital 67.7 73.4 141.1 % Growth +19.5% +21.2% +20.3% Bio Supplies 107.3 118.5 225.8 % Growth (8.5%) +22.0% +4.8% Others & Intersegment (19.9) (8.0) (27.9) Total 2,536.6 2,396.5 4,933.1 % Growth +2.3% (9.8%) (3.7%) 2021 Highlights Full Year Performance Marked by a Challenging Second Half U.S. + Canada 64% EU 18% ROW 18% 8.7% 1.3% -7.9% 4.9bn Note: all growths at constant currency (cc), which excludes exchange rate fluctuations period over period, and vs. PY (EUR in millions)

- 10 - 2021 Full Year Results Revenues – Bioscience Growth Constrained by Plasma Supply Underlying demand remains strong across key proteins. Plasma supply constraints impacted IG volume growth. Gross margin impacted by lower plasma volume and high cost per liter, partially offset by price increases. IVIG U.S. volume impacted by plasma supply constrains partially offset by mid-single-digit price increases. Higher volume demand and notable price increases in EU and Canada Alpha-1 High-single digit growth backed by U.S. higher volume and price. Prolastin launched in France and higher demand in key European countries Albumin Mid-single digit growth driven by China and MEA countries. ALBUTEIN FlexBag™ introduced in November 2021 Specialty proteins Mid-single digit growth supported by Anti-Rabies and Anti-T in U.S. and Anti-H in South America and APAC. Tetanus vaccine increased mid-to-high single digit due to higher demand in U.S. New Product Contributions Xembify® +55% higher SCIG demand post launch Vistaseal™ +10% driven by European launch and U.S. market position Tavlesse® gaining traction after 2H’20 launch Note: all growths at constant currency (cc), which excludes exchange rate fluctuations period over period, and vs. PY IG [50-55%] Albumin [15-20%] Alpha-1 [15-20%] Specialty Proteins [10-15%]

- 11 - 2021 Full Year Results Prospects Grifols is trailing the industry recovery trend Current upward trajectory to continue and accelerate throughout 2022, leveraging on: • Further contribution from new and acquired plasma centers • Plasma capacity installed available: up to 60% • New donor compensation scheme • Increase in talent retention • Digital evolution to drive headcount optimization, software automation, and flow-time reduction • Enhancing digital marketing Grifols Plasma Collection Recovery Plasma Collections COVID-19 outbreak 60 70 80 90 100 110 120 130 140 2022 -4% FY21 vs. FY20 +4% Pandemic Period Q2 to Q4 2021 vs. PY Q1 Q3 Q4 2020 Q2 Q1 Q3 Q4 2021 Q2 U.S. fiscal programs Holiday seasonal impact Weekly evolution of plasma collections in the U.S. and Europe • Delta variant • B1/B2 Visa issue • High-donor fee tapers off Note: Weekly collections until Week 6 of 2022

- 12 - 2021 Full Year Results • +54 new and recently acquired centers: +c.2mL capacity • Europe overtakes 2019 levels, representing >10% of total plasma volumes in 2021 • Vaccination rollouts • Easing of COVID-19 restrictions Grifols Plasma Collection Recovery Plasma Collections • Disruption from Delta and Omicron COVID- 19 variants • Continuous U.S. government assistance: direct payments and further fiscal stimulus programs • Mexico Border and B1/B2 visa restriction impeding donations during this period • Fear of infection continued despite strong safety measures x3 2021 2022 Headwinds Tailwinds Weekly evolution of plasma collections in new and acquired centers in U.S. and EU Note: Weekly collections until Week 6 of 2022

- 13 - 2021 Full Year Results Revenues – Diagnostic +3.5% Growth Backed by COVID-19 Innovation Mid-single digit growth driven by strong COVID tests in H1 2021 and Blood Typing Solutions, partially offset by Zika testing mandate termination NAT Donor Screening Mid-single digit growth driven by COVID-19 tests in Spain and Hungary. Underlying NAT Donor Screening decreased low-single digit driven by strong U.S. and Japan whole-blood donations offset by Zika testing termination Recom. Proteins Down mid-single digit driven by lower joint-business sales Blood Typing Solutions Mid-single digit growth due to higher volume in the U.S. partially offset by Turkey, China and Mexico Donor screening [60-65%] Blood typing solutions [15-20%] Recombinant proteins [10-15%] Others [5-10%] Temporary Product Contribution Note: all growths at constant currency (cc), which excludes exchange rate fluctuations period over period, and vs. PY COVID-19 tests €110m +34% vs. PY

- 14 - 2021 Full Year Results IV Therapy Increase by low-double-digit driven by higher sales of anticoagulant and saline solutions to donor centers. Higher sales in Iberia and in U.S. Revenues – Hospital Strong Performance Delivering +20% in 2021 Double digit growth following normalization of hospital pharmacy investments. All segments recovering positively Pharmatech Double-digit growth driven by Pharmacy Keeper in U.S. and Misteriums projects in IBAM and Hospital Logistic in Spain and LATAM Medical Increase low double-digit growth backed by business turnaround in Spain Contract Manuf. Strong growth mainly due to higher sales of albumin bags and third parties Pharmatech [35-40%] IV Therapy [30-35%] Contract manufacturing [10-15%] Others [15-20%] Note: all growths at constant currency (cc), which excludes exchange rate fluctuations period over period, and vs. PY

- 15 - 2021 Full Year Results Bio Supplies Commercial Down high-single digit driven by lower sales of blood cells and serum due to lower donations. Bio Supplies Biopharma increased low-single digit mainly due to sales of NTU albumin and cell culture media Revenues – Bio Supplies Reporting +5% Growth in 2021 Plasma to 3rd parties Increase based on pre-existing supply agreements regarding plasma- centers acquisitions Commercial [50-55%] Plasma [35-40%] Others [5-10%] Note: all growths at constant currency (cc), which excludes exchange rate fluctuations period over period, and vs. PY

- 16 - 2021 Full Year Results 19.5% 28.1% 24.8% EBITDA Bridge 2021 vs. 2020 Underlying EBITDA Highlights Strong Fundamentals 220 146 132 503 52 54 Underlying EBITDA FY20 1,544 Reported EBITDA FY20 Fx Reported EBITDA FY21 Underlying EBITDA FY21 (cc) New companies*, Zika, inflationary pressures and others SRAAS 12 Price, cost savings plan, new launches and others COVID impact 2020 1,324 1,570 961 Transaction, restructuring and one-offs COVID impact 2021 * Includes Alkahest, GigaGen, Green Cross and Plasmavita (EUR in millions) 27.6%

- 17 - 2021 Full Year Results COVID-19 Impact Cost Per Liter to Improve Significantly as Recovery Progresses 503 COVID impact 2021 183 Under absorption 150 Donor compensation 238 Sales volumen 68 NAT Covid • Stay-at-home orders, quarantines, restricted movement and fear of disease • Travel restrictions (specifically U.S. border closure with Mexico) • Government stimulus programs Revenues growth and EBITDA margins to boost once supply constraints are lifted Lower plasma collections improving as recovery progresses… Higher Cost Per Liter (CPL) moderates as recovery progresses… • Higher compensation paid to donors • Lower absorption of fixed costs at donor centers and manufacturing facilities Expected cost reduction once U.S. stimulus packages are well absorbed Expected to resolve due to normalized donation volumes and realization of scale efficiencies, significant operational leverage (EUR in millions) €420m volume-related

- 18 - 2021 Full Year Results Financial Position Strategically Invested to Support and Accelerate Sustainable Growth Acquisitions €520m Innovation €126m Plasma €394m CAPEX €281m Enhancing fractionation and purification capabilities • New 6mL plasma fractionation plant in Clayton, North Carolina (U.S.) • World’s first sterile purification and filling plant in Clayton • New albumin purification and sterile filling plant for flexible containers (bags) in Dublin (Ireland) • Expansion of the fibrin adhesive and topical thrombin production plant in Barcelona (Spain) • Upgrade Grifols’ facilities in Canada Strengthening innovation ecosystem • Alkahest – to enhance discovery research and development to identify innovative therapies for age- related diseases based upon an understanding of the human plasma proteome • GigaGen – to boost a novel method to generate a wide range of immunoglobulins Expanding and diversifying plasma assets • 25 U.S.-based plasma centers from BPL • 7 U.S.-based plasma centers from Kedrion • 1 plasma center in Egypt, as part of the first plasma-supply platform in Africa in collaboration with the National Service Projects Organization (NSPO) • 1 plasma center in Canada from Kedrion

- 19 - 2021 Full Year Results Cash & Cash Equivalents 1 €655m Financial Position Sound Financial Position FY21 Reported 1.7 COVID impact 2021 FY21 (excl. 2021 COVID impact) 3.7x 5.4x Liquidity €1.3bn 1 Not including Biotest investment financed cash proceeds 2Biotest financed transaction not impacting net debt as of December 31, 2021 2021 Leverage Ratio2 Operating Cash Flow €597m GIC capital injection $1bn

- 20 - 2021 Full Year Results Financial Position No Significant Debt Maturities Until 2025 1,951 2,000 129 40 66 1,904 56 3,951 2,033 2022 2023 2024 2025 2026 2027 2028 HYB to acquire Biotest Key Financial Conditions • Average rate of 2.6% • Average tenor of 5.5 years Amortization Schedule (EUR in millions)

3. Prospects

- 22 - 2021 Full Year Results A Transformational Investment1 Unique opportunity to launch two new, currently unused plasma proteins in the short- term, significantly improving margins Significant revenue and cost synergies leading to a highly accretive investment More balanced global footprint by expanding operations (+28 centers) and revenues in EMEA, while broadening Biotest footprint in the U.S. Integrate and accelerate an attractive pipeline of innovative therapies with exceptional potential growth and profit from 2023 onwards Leading industrial capacity up to 20m/L (combined) 1 Regulatory approvals and customary conditions to be obtained

- 23 - 2021 Full Year Results On track Expected to close by H1’22 as regulatory approvals and customary conditions upon clearance January’22 1H’22 November 5, 2021 Joint reasoned statement of Biotest – Management Board & Supervisory Board recommend to accept Grifols takeover offer “… see in the business combination a concrete opportunity to combine the existing resources of Grifols and Biotest in the field of blood plasma in order to achieve a greater availability of resources as well as a larger product range. Grifols increase of available resources for Biotest's research and development departments could also drive product development and manufacturing faster than would be possible for Biotest as an individual company.” PTO level of acceptance >95% of the voting rights ~70% of the share capital • Offer accepted by ~43% of the preferred shares • A put period of 3 months until April 21, 2022 is open for the remaining non-controlled ordinary shares (with voting rights)

- 24 - 2021 Full Year Results Prospects Proven Track-Record to Lead The Industry Plasma Plasma collections to accelerate throughout 2022 to recover pre-COVID levels. Driven by new plasma centers and recent acquisitions, along with mature centers, and technological, digital and operational improvements while pandemic easing Revenues Sound revenue growth as plasma recovers, backed by strong underlying demand across key proteins, price increases and product and geo mix Margins Sequential increase as plasma fully recovers, triggering cost per liter reduction through realization of scale efficiencies; and positive price environment. Volume recovery will lead significant operational leverage Lean organization • R&D prioritization (EUR 40m savings) • 100m structural cost plan (60% in 2022 and 40% in 2023) • Divestment of non-strategic assets • Identifying and challenging cost reduction opportunities Executing on pipeline • End Point Health global partnership to develop the use of ATIII in Sepsis • Advancing on SCIG (approved in EU), ATIII in Trauma, Albumin in Sepsis and liver-related disease • New confirmatory trial for Alzheimer

- 25 - 2021 Full Year Results Fundamentals Remains Robust Despite Short-Term Challenges Sustainable financial performance in a solid industry Note: Global market share as per FY2020 Leading position within top 3 players of the industry. Unchanged strong market share in plasma collection business Robust underlying demand coupled by strong volume growth and price increases across key regions Plasma collections to accelerate throughout 2022 as the industry’s recovery trend gains strength Strategically invested in our plasma and industrial capacity and capabilities Broadening commercial pipeline with non-plasma assets Biotest transformational acquisition to improve plasma economics Leaner and more flexible organization Potential new uses for existing and new proteins

Annexes

Net Revenue by Division * Constant currency (cc) excludes exchange rate fluctuations period over period In thousands of euros FY 2021 FY 2020 % Var % Var cc* 2H 2021 2H 2020 % Var % Var cc* 1H 2021 1H 2020 % Var % Var cc* BIOSCIENCE 3,814,983 4,242,502 (10.1%) (5.9%) 1,828,959 2,083,650 (12.2%) (12.0%) 1,986,024 2,158,852 (8.0%) (0.1%) DIAGNOSTIC 779,108 775,889 0.4% 3.5% 383,625 435,877 (12.0%) (11.7%) 395,483 340,012 16.3% 22.9% HOSPITAL 141,190 118,675 19.0% 20.3% 73,440 60,812 20.8% 21.2% 67,750 57,863 17.1% 19.5% BIO SUPPLIES 225,766 224,090 0.7% 4.8% 118,506 97,372 21.7% 22.0% 107,260 126,718 (15.4%) (8.5%) OTHERS 39,620 31,989 23.9% 27.2% 24,132 13,332 81.0% 81.3% 15,488 18,657 (17.0%) (11.5%) INTERSEGMENTS (67,549) (53,107) 27.2% 31.6% (32,176) (28,346) 13.5% 14.0% (35,373) (24,761) 42.9% 51.7% TOTAL 4,933,118 5,340,038 (7.6%) (3.7%) 2,396,486 2,662,697 (10.0%) (9.8%) 2,536,632 2,677,341 (5.3%) 2.3% In thousands of euros FY 2021 FY 2020 % Var % Var cc* 2H 2021 2H 2020 % Var % Var cc* 1H 2021 1H 2020 % Var % Var cc* BIOSCIENCE 3,814,983 4,242,502 (10.1%) (5.9%) 1,828,959 2,083,650 (12.2%) (12.0%) 1,986,024 2,158,852 (8.0%) (0.1%) DIAGNOSTIC 779,108 775,889 0.4% 3.5% 383,625 435,877 (12.0%) (11.7%) 395,483 340,012 16.3% 22.9% HOSPITAL 141,190 118,675 19.0% 20.3% 73,440 60,812 20.8% 21.2% 67,750 57,863 17.1% 19.5% BIO SUPPLIES 113,600 123,953 (8.4%) (5.4%) 62,138 62,911 (1.2%) (0.7%) 51,462 61,041 (15.7%) (10.3%) OTHERS 39,620 31,989 23.9% 27.2% 24,132 13,332 81.0% 81.3% 15,488 18,657 (17.0%) (11.5%) INTERSEGMENTS (67,549) (53,107) 27.2% 31.6% (32,176) (28,346) 13.5% 14.0% (35,373) (24,761) 42.9% 51.7% TOTAL (Excl. Plasma sales 3rd party) 4,820,952 5,239,901 (8.0%) (4.1%) 2,340,118 2,628,236 (11.0%) (10.7%) 2,480,834 2,611,664 (5.0%) 2.5% Plasma sales 3rd party 112,166 100,137 12.0% 56,368 34,461 63.6% 55,798 65,677 (15.0%) TOTAL 4,933,118 5,340,038 (7.6%) (3.7%) 2,396,486 2,662,697 (10.0%) (9.8%) 2,536,632 2,677,341 (5.3%) 2.3%

Net Revenue by Region In thousands of euros FY 2021 FY 2020 % Var % Var cc* 2H 2021 2H 2020 % Var % Var cc* 1H 2021 1H 2020 % Var % Var cc* US + CANADA 3,154,548 3,599,746 (12.4%) (7.9%) 1,577,655 1,755,170 (10.1%) (9.7%) 1,576,893 1,844,576 (14.5%) (6.1%) EU 906,449 834,492 8.6% 8.7% 453,913 458,050 (0.9%) (0.9%) 452,536 376,442 20.2% 20.5% ROW 872,121 905,800 (3.7%) 1.3% 364,918 449,477 (18.8%) (19.0%) 507,203 456,323 11.1% 21.3% TOTAL 4,933,118 5,340,038 (7.6%) (3.7%) 2,396,486 2,662,697 (10.0%) (9.8%) 2,536,632 2,677,341 (5.3%) 2.3% * Constant currency (cc) excludes exchange rate fluctuations period over period

Profit and Loss In thousands of euros 2021 2020 % Var 2H 2021 2H 2020 % Var 1H 2021 1H 2020 % Var NET REVENUES 4,933,118 5,340,038 (7.6%) 2,396,486 2,662,697 (10.0%) 2,536,632 2,677,341 (5.3%) COST OF SALES (2,970,522) (3,084,873) (3.7%) (1,548,013) (1,446,150) 7.0% (1,422,509) (1,638,723) (13.2%) GROSS MARGIN 1,962,596 2,255,165 (13.0%) 848,473 1,216,547 (30.3%) 1,114,123 1,038,618 7.3% % Net revenues 39.8% 42.2% 35.4% 45.7% 43.9% 38.8% R&D (354,881) (294,216) 20.6% (196,339) (152,103) 29.1% (158,542) (142,113) 11.6% SG&A (1,061,508) (985,616) 7.7% (554,506) (501,249) 10.6% (507,002) (484,367) 4.7% OPERATING EXPENSES (1,416,389) (1,279,832) 10.7% (750,845) (653,352) 14.9% (665,544) (626,480) 6.2% OTHER INCOME 16,302 - 16,302 --- SHARE OF RESULTS OF EQUITY ACCOUNTED INVESTEES - CORE ACTIVITIES 32,555 20,799 56.5% 17,584 11,241 56.4% 14,971 9,558 56.6% OPERATING RESULT (EBIT) 595,064 996,132 (40.3%) 131,514 574,436 (77.1%) 463,550 421,696 9.9% % Net revenues 12.1% 18.7% 5.5% 21.6% 18.3% 15.8% FINANCIAL RESULT (277,799) (177,669) 56.4% (158,362) (101,740) 55.7% (119,437) (75,929) 57.3% SHARE OF RESULTS OF EQUITY ACCOUNTED INVESTEES 33,188 60,166 (44.8%) (934) 78,788 (101.2%) 34,122 (18,622) (283.2%) PROFIT BEFORE TAX 350,453 878,629 (60.1%) -27,782 551,484 (105.0%) 378,235 327,145 15.6% % Net revenues 7.1% 16.5% (1.2%) 20.7% 14.9% 12.2% INCOME TAX EXPENSE (85,126) (169,639) (49.8%) (9,479) (104,170) (90.9%) (75,647) (65,469) 15.5% % of pre-tax income 24.3% 19.3% 34.1% 18.9% 20.0% 20.0% CONSOLIDATED PROFIT 265,327 708,990 (62.6%) (37,261) 447,314 (108.3%) 302,588 261,676 15.6% RESULT ATTRIBUTABLE TO NON-CONTROLLING INTERESTS 82,524 90,444 (8.8%) 46,751 47,015 (0.6%) 35,773 43,429 (17.6%) GROUP PROFIT 182,803 618,546 (70.4%) (84,012) 400,299 (121.0%) 266,815 218,247 22.3% % Net revenues 3.7% 11.6% (3.5%) 15.0% 10.5% 8.2%

Cash Flow In thousands of euros 2021 2020 REPORTED GROUP PROFIT 182,803 618,546 DEPRECIATION AND AMORTIZATION 359,767 321,533 NET PROVISIONS 64,092 (17,148) OTHER ADJUSTMENTS AND OTHER CHANGES IN WORKING CAPITAL 186,606 28,888 CHANGES IN INVENTORIES (157,474) 164,632 CHANGES IN TRADE RECEIVABLES (39,227) (40,339) CHANGES IN TRADE PAYABLES 408 34,224 CHANGE IN OPERATING WORKING CAPITAL (196,293) 158,517 NET CASH FLOW FROM OPERATING ACTIVITIES 596,975 1,110,336 BUSINESS COMBINATIONS AND INVESTMENTS IN GROUP COMPANIES (519,128) (468,590) CAPEX (280,889) (308,092) R&D/OTHER INTANGIBLE ASSETS (34,199) (54,467) OTHER CASH INFLOW / (OUTFLOW) 804,823 (26,966) NET CASH FLOW FROM INVESTING ACTIVITIES (29,393) (858,115) FREE CASH FLOW 567,582 252,221 PROCEEDS FROM / (PAYMENTS) FOR EQUITY INSTRUMENTS (125,703) 0 ISSUE / (REPAYMENT) OF DEBT 1,878,515 (243,373) DIVIDENDS (PAID) / RECEIVED (247,498) (103,075) OTHER CASH FLOWS FROM/(USED IN) FINANCING ACTIVITIES (32,391) (7,953) NET CASH FLOW FROM FINANCING ACTIVITIES 1,472,923 (354,401) TOTAL CASH FLOW 2,040,505 (102,180) CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR 579,647 741,982 EFFECT OF EXCHANGE RATE CHANGES IN CASH AND CASH EQUIVALENTS 55,459 (60,155) CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD 2,675,611 579,647

Balance Sheet ASSETS In thousands of euros December December 2021 2020 NON-CURRENT ASSETS 13,723,555 12,109,822 GOODWILL AND OTHER INTANGIBLE ASSETS 8,661,508 7,568,617 PROPERTY PLANT & EQUIPMENT 2,547,497 2,324,107 INVESTMENTS IN EQUITY ACCOUNTED INVESTEES 1,999,776 1,869,020 NON-CURRENT FINANCIAL ASSETS 362,267 198,157 OTHER NON-CURRENT ASSETS 152,507 149,921 CURRENT ASSETS 5,510,280 3,164,954 INVENTORIES 2,259,354 2,002,281 CURRENT CONTRACT ASSETS 1,939 TRADE AND OTHER RECEIVABLES 499,708 520,158 OTHER CURRENT FINANCIAL ASSETS 2,029,707 11,118 OTHER CURRENT ASSETS 64,079 51,750 CASH AND CASH EQUIVALENTS 655,493 579,647 TOTAL ASSETS 19,233,835 15,274,776 EQUITY AND LIABILITIES In thousands of euros December December 2021 2020 EQUITY 8,147,035 6,720,055 CAPITAL 119,604 119,604 SHARE PREMIUM 910,728 910,728 RESERVES 4,710,787 3,776,932 TREASURY STOCK (164,189) (43,734) CURRENT YEAR EARNINGS 182,803 618,546 OTHER COMPREHENSIVE INCOME 336,910 (273,684) NON-CONTROLLING INTERESTS 2,050,392 1,611,663 NON-CURRENT LIABILITIES 7,612,488 7,219,583 NON-CURRENT FINANCIAL LIABILITIES 6,939,013 6,602,100 OTHER NON-CURRENT LIABILITIES 673,475 617,483 CURRENT LIABILITIES 3,474,312 1,335,138 CURRENT FINANCIAL LIABILITIES 2,438,291 424,612 OTHER CURRENT LIABILITIES 1,036,021 910,526 TOTAL EQUITY AND LIABILITIES 19,233,835 15,274,776

- 32 - 2021 Full Year Results Investor Relations & Sustainability +34 93 571 02 21 inversores@grifols.com sostenibilidad@grifols.com investors@grifols.com sustainability@grifols.com